Overview

Desensitization of Renal Transplant Candidates

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
0
Participant gender:
All
Summary
Trial of the use of Myfortic to reduce anti-HLA alloantibody in patients waiting for renal transplantation.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Florida
Collaborator:
Novartis
Treatments:
Mycophenolate mofetil
Mycophenolic Acid
Criteria
Inclusion Criteria:

- Patients on the deceased donor kidney transplant waiting list with panel reactive
antibodies >50% and living donor waiting list patients who have a history of a
positive crossmatch (donor-specific antibodies) will be eligible for the study.

Exclusion Criteria:

- Any subjects not meeting the Inclusion Criteria

- Subjects unable to attend weekly clinic visits for six weeks

- Inability to tolerate Myfortic